🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to share our work in Nature Biomedical Engineering developing methods for non-viral intron engineering of CAR-T cells with large synthetic DNA sequences @ TheoRoth Parker Institute for Cancer Immunotherapy nature.com/articles/s4155…

Early career funding is essential for the future of science and medicine. Awesome that CRI is expanding its postdoc programs! Please apply to the immuno-informatics program here: cancerresearch.org/immuno-informa…

Thrilled to share our latest work in Cancer Cell! 🚨Led by @chenweller, Osnat Bartok, with amazing collaborators @Chrismcginnis, @AnsumanSatpathy, Andreas Schlosser, Eytan Ruppin, MD, PhD & more, we reveal that impaired translation fidelity enhances anti-tumor immunity!🧵(1/7)

congratulations to Chen Weller and Osnat Bartok in yardena samuels lab and Chris McGinnis in our lab on this exciting story. Targeting translational fidelity can lead to new targetable cancer antigens!

America built the biotech revolution. But FDA red tape and policy that discourages US bio-manufacturing is strangling our innovation and handing the future to China. We've watched this happen in other industries. Our new essay shows how the administration can fix it and restore

We Wing VC are thrilled to support Goodfire's $50M Series A. As foundation models grow more powerful and pervasive, especially in non-semantic domains like biology, chemistry, and physics, enterprises will need more than just outputs. They’ll need to understand how their

congrats to the Goodfire team! AI interpretability will be a game-changer for biology. Eric Ho Tom McGrath Dan Balsam Zach DeWitt

Thrilled to kick off this important collaboration. ⁦Immunai⁩ and the ⁦Parker Institute for Cancer Immunotherapy⁩ Collaborate to Build One of the Largest Single-Cell Datasets in Cancer #scRNAseq #realworlddata search.app/aGdAhWRA7QzoGY…

so cool to see 3 of my favorite teams working together! Parker Institute for Cancer Immunotherapy Immunai 10x Genomics

great perspective from Alex Kolicich

really cool

congratulations to Jacob Kimmel Blake Byers and team - great to see people driving hard towards innovative medicines!

I once quit a study section mid-review because a reviewer gave an exceptionally productive physician-scientist trainee (after 15 years of training) a non-fundable K08 score because of small deficiencies in their animal protocol. He said he was being 'fair.' I yelled at him and

Absolutely thrilled to share with you the final version of EPIclone, out now (open access) in nature. This has been an amazing collaboration with the lab of Lars Velten (@larsplus) at Centre for Genomic Regulation (CRG) nature.com/articles/s4158…

awesome clone tracing method and story from Alejo Rodriguez-Fraticelli, PhD and colleagues

wort drizla Jing Liang 🇺🇦 If antigen expression is tightly restricted and tumor-specific, like KLK2 versus PSMA, then unmasked TCEs could offer a better therapeutic index without the risk of premature systemic activation.

Solving the "replication crisis" is dumb because (1) it's not a crisis, (2) the medicine is worse than the disease. Much of this is because people want science to be more like engineering, and it's not. It's fundamentally different and trying to treat engineering processes like

We are pleased to share our work evaluating some of the latest single-cell platforms, including updated chemistries, in two separate experiments using peripheral blood mononuclear cells (PBMCs). biorxiv.org/cgi/content/sh…

About a year ago I thought how it must be nice to be building a company working with known tx modality going after known targets. Now I think that the only way to win in biotech is to be building anything but that.